|
DE60305919T2
(de)
*
|
2002-06-28 |
2007-01-18 |
Domantis Limited, Cambridge |
Dual-specifische liganden mit erhöhter halbwertszeit
|
|
DK2330121T3
(da)
*
|
2004-06-02 |
2014-12-15 |
Adalta Pty Ltd |
Bindingsdele baseret på haj-IgNar-domæner
|
|
US7563443B2
(en)
|
2004-09-17 |
2009-07-21 |
Domantis Limited |
Monovalent anti-CD40L antibody polypeptides and compositions thereof
|
|
WO2009012181A2
(en)
|
2007-07-13 |
2009-01-22 |
Ventana Medical Systems, Inc. |
Method of identifying diagnostic reagents
|
|
PE20091163A1
(es)
|
2007-11-01 |
2009-08-09 |
Wyeth Corp |
Anticuerpos para gdf8
|
|
CA2960659C
(en)
|
2007-11-09 |
2021-07-13 |
The Salk Institute For Biological Studies |
Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors
|
|
EP2615115A3
(en)
|
2007-11-30 |
2014-01-08 |
Glaxo Group Limited |
Antigen-binding constructs
|
|
NZ590605A
(en)
|
2008-07-09 |
2012-11-30 |
Biogen Idec Inc |
Compositions comprising antibodies to lingo or fragments thereof
|
|
JP5675608B2
(ja)
|
2008-07-18 |
2015-02-25 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
Ｃｄ２８結合のための一価組成物および使用方法
|
|
EP2344180A2
(en)
|
2008-09-23 |
2011-07-20 |
Wyeth LLC |
Methods for predicting production of activating signals by cross-linked binding proteins
|
|
WO2010056550A1
(en)
|
2008-10-29 |
2010-05-20 |
Wyeth Llc |
Methods for purification of single domain antigen binding molecules
|
|
KR101593285B1
(ko)
|
2008-10-29 |
2016-02-11 |
아블린쓰 엔.브이. |
단일 도메인 항원 결합 분자의 제형
|
|
CA2750520C
(en)
|
2009-02-04 |
2017-12-05 |
Molecular Innovations |
Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin, and antibodies used therein
|
|
EP2401298A1
(en)
|
2009-02-24 |
2012-01-04 |
Glaxo Group Limited |
Antigen-binding constructs
|
|
CA2753332A1
(en)
|
2009-02-24 |
2010-09-02 |
Glaxo Group Limited |
Antigen-binding constructs
|
|
WO2010097394A1
(en)
|
2009-02-24 |
2010-09-02 |
Glaxo Group Limited |
Multivalent and/or multispecific rankl-binding constructs
|
|
CA3031851C
(en)
|
2009-10-23 |
2020-07-07 |
Amgen British Columbia |
Anti-gcc antibody molecules and related compositions and methods
|
|
US8496933B2
(en)
|
2009-11-04 |
2013-07-30 |
Laboratorios Silanes, S.A. De C.V. |
VHNAR anti-cytokine domains
|
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
|
CA3079122A1
(en)
|
2010-03-26 |
2011-09-29 |
Trustees Of Dartmouth College |
Vista regulatory t cell mediator protein, vista binding agents and use thereof
|
|
CA2805572A1
(en)
|
2010-07-16 |
2012-01-19 |
Martin Hegen |
Modified single domain antigen binding molecules and uses thereof
|
|
LT2643352T
(lt)
|
2010-11-23 |
2018-08-10 |
Glaxo Group Limited |
Antigeną onkostatiną m (osm) surišantys baltymai
|
|
WO2012069557A1
(en)
|
2010-11-24 |
2012-05-31 |
Glaxo Group Limited |
Multispecific antigen binding proteins targeting hgf
|
|
WO2012103240A2
(en)
|
2011-01-25 |
2012-08-02 |
Eleven Biotherapeutics, Inc. |
Receptor binding agents
|
|
KR102058254B1
(ko)
|
2011-03-29 |
2019-12-20 |
글락소스미스클라인 엘엘씨 |
단백질 정제용 완충제 시스템
|
|
EP3058952A1
(en)
|
2011-04-07 |
2016-08-24 |
Glaxosmithkline LLC |
Formulations with reduced viscosity
|
|
US9409987B2
(en)
|
2011-04-15 |
2016-08-09 |
Compugen Ltd |
Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
|
|
PE20141045A1
(es)
|
2011-05-27 |
2014-09-10 |
Glaxo Group Ltd |
Proteinas de union a bcma (cd269/tnfrsf17)
|
|
WO2013033073A1
(en)
|
2011-08-31 |
2013-03-07 |
Ventana Medical Systems, Inc. |
Expression of ets related gene (erg) and phosphatase and tensin homolog (pten) correlates with prostate cancer capsular penetration
|
|
GB2502127A
(en)
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
|
US9156915B2
(en)
|
2012-04-26 |
2015-10-13 |
Thomas Jefferson University |
Anti-GCC antibody molecules
|
|
WO2013167883A1
(en)
|
2012-05-07 |
2013-11-14 |
The University Court Of The University Of Aberdeen |
Single domain binding molecule
|
|
KR102142161B1
(ko)
|
2012-05-14 |
2020-08-06 |
바이오젠 엠에이 인코포레이티드 |
운동 뉴런 관련 병태 치료용 lingo-2 길항제
|
|
BR112014032276A2
(pt)
|
2012-06-22 |
2017-11-28 |
King S College London |
construtos de vista-ig e o uso de vista-ig para o tratamento de distúrbios autoimunes, alérgicos e inflamatórios
|
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
|
EP2877211A4
(en)
|
2012-07-25 |
2016-02-10 |
Salk Inst For Biological Studi |
CONTROL OF INTERACTION BETWEEN TAM LIGANDS AND LIPID MEMBRANES WITH EXPOSED PHOSPHATIDYL SERININE
|
|
EP3552628A1
(en)
|
2012-09-07 |
2019-10-16 |
The Trustees Of Dartmouth College |
Vista modulators for diagnosis and treatment of cancer
|
|
CN109364250A
(zh)
|
2012-10-09 |
2019-02-22 |
比奥根Ma公司 |
联合治疗及用于治疗脱髓鞘病症的用途
|
|
WO2014120916A1
(en)
|
2013-02-01 |
2014-08-07 |
Bristol-Myers Squibb Company |
Pegylated domain antibodies monovalent for cd28 binding and methods of use
|
|
EP2762496A1
(en)
|
2013-02-05 |
2014-08-06 |
EngMab AG |
Method for the selection of antibodies against BCMA
|
|
US10077315B2
(en)
|
2013-02-05 |
2018-09-18 |
Engmab Sàrl |
Bispecific antibodies against CD3 and BCMA
|
|
EP3444278A1
(en)
|
2013-02-26 |
2019-02-20 |
Roche Glycart AG |
Bispecific t cell activating antigen binding molecules
|
|
KR101990341B1
(ko)
|
2013-03-12 |
2019-06-19 |
몰레큘러 템플레이츠, 인코퍼레이션. |
세포 내재화를 유도하기 위한 ｃｄ20-결합 면역독소 및 이의 사용 방법
|
|
WO2014141149A1
(en)
|
2013-03-15 |
2014-09-18 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Formulations with reduced viscosity
|
|
CN105051203A
(zh)
|
2013-03-15 |
2015-11-11 |
葛兰素史克知识产权第二有限公司 |
三羧酸(tca)中间体用于控制细胞培养中的氨产生的用途
|
|
US9745368B2
(en)
|
2013-03-15 |
2017-08-29 |
The Trustees Of The University Of Pennsylvania |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
AU2014229280B2
(en)
|
2013-03-15 |
2017-01-05 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Methods for purifying antibodies
|
|
RU2015137685A
(ru)
|
2013-03-15 |
2017-04-20 |
ГлаксоСмитКлайн Интеллекчуал Проперти (N2) Лимитед |
Композиции антитела в низкой концентрации
|
|
EP2789630A1
(en)
|
2013-04-09 |
2014-10-15 |
EngMab AG |
Bispecific antibodies against CD3e and ROR1
|
|
WO2014173975A1
(en)
|
2013-04-23 |
2014-10-30 |
The University Court Of The University Of Aberdeen |
Isolation of therapeutic target specific vnar domains to icosl
|
|
NL1040254C2
(en)
|
2013-05-17 |
2014-11-24 |
Ablynx Nv |
Stable formulations of immunoglobulin single variable domains and uses thereof.
|
|
WO2015090230A1
(en)
|
2013-12-19 |
2015-06-25 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
|
JP6793902B2
(ja)
|
2013-12-20 |
2020-12-02 |
ノバルティス アーゲー |
調節可能キメラ抗原受容体
|
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
|
WO2015100246A1
(en)
|
2013-12-24 |
2015-07-02 |
Ossianix, Inc. |
Baff selective binding compounds and related methods
|
|
AU2014372309C1
(en)
|
2013-12-24 |
2017-12-14 |
Janssen Pharmaceutica Nv |
Anti-VISTA antibodies and fragments
|
|
WO2015142661A1
(en)
|
2014-03-15 |
2015-09-24 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
|
ES2939760T3
(es)
|
2014-03-15 |
2023-04-26 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico para antígenos
|
|
TWI694836B
(zh)
|
2014-05-16 |
2020-06-01 |
英商葛蘭素史克智慧財產管理有限公司 |
抗體調配物
|
|
MX389695B
(es)
|
2014-06-11 |
2025-03-20 |
Kathy A Green |
Uso de agonistas y antagonistas vista para suprimir o aumentar la inmunidad humoral.
|
|
WO2015200883A2
(en)
|
2014-06-26 |
2015-12-30 |
Ossianix, Inc. |
Semi-synthetic nurse shark vnar libraries for making and using selective binding compounds
|
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
|
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
EP3722316A1
(en)
|
2014-07-21 |
2020-10-14 |
Novartis AG |
Treatment of cancer using a cd33 chimeric antigen receptor
|
|
JP7054622B2
(ja)
|
2014-07-21 |
2022-04-14 |
ノバルティス アーゲー |
ヒト化抗ｂｃｍａキメラ抗原受容体を使用した癌の処置
|
|
ES2781175T3
(es)
|
2014-07-31 |
2020-08-31 |
Novartis Ag |
Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico
|
|
ES2791248T3
(es)
|
2014-08-19 |
2020-11-03 |
Novartis Ag |
Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer
|
|
US10577417B2
(en)
|
2014-09-17 |
2020-03-03 |
Novartis Ag |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
JP6708635B2
(ja)
|
2014-10-09 |
2020-06-10 |
エンクマフ エスアーエールエル |
ＣＤ３εおよびＲＯＲ１に対する二特異性抗体
|
|
WO2016059602A2
(en)
|
2014-10-16 |
2016-04-21 |
Glaxo Group Limited |
Methods of treating cancer and related compositions
|
|
AU2015346045B2
(en)
|
2014-11-14 |
2021-08-26 |
Ossianix, Inc. |
Variable new antigen receptors (VNARs) directed against transferrin receptor (TfR) and their use
|
|
US20180334490A1
(en)
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
|
CN107405398A
(zh)
|
2014-12-05 |
2017-11-28 |
伊穆奈克斯特股份有限公司 |
鉴定vsig8作为推定vista受体及其用以产生vista/vsig8激动剂和拮抗剂的用途
|
|
IL253149B2
(en)
|
2014-12-29 |
2023-11-01 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
US10435467B2
(en)
|
2015-01-08 |
2019-10-08 |
Biogen Ma Inc. |
LINGO-1 antagonists and uses for treatment of demyelinating disorders
|
|
US11161907B2
(en)
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
WO2016164580A1
(en)
|
2015-04-07 |
2016-10-13 |
Novartis Ag |
Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
|
|
WO2016168595A1
(en)
|
2015-04-17 |
2016-10-20 |
Barrett David Maxwell |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
|
US12128069B2
(en)
|
2015-04-23 |
2024-10-29 |
The Trustees Of The University Of Pennsylvania |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
CN107922497B
(zh)
|
2015-06-24 |
2022-04-12 |
詹森药业有限公司 |
抗vista抗体和片段
|
|
AR105433A1
(es)
|
2015-07-21 |
2017-10-04 |
Novartis Ag |
Métodos para mejorar la eficacia y expansión de las células inmunes
|
|
CA2992797A1
(en)
|
2015-08-03 |
2017-02-09 |
Engmab Sarl |
Monoclonal antibodies against bcma
|
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
|
WO2017040930A2
(en)
|
2015-09-03 |
2017-03-09 |
The Trustees Of The University Of Pennsylvania |
Biomarkers predictive of cytokine release syndrome
|
|
BR112018008799A2
(pt)
|
2015-10-30 |
2019-01-15 |
Glaxosmithkline Ip Dev Ltd |
método de prognóstico
|
|
EP3393504B1
(en)
|
2015-12-22 |
2025-09-24 |
Novartis AG |
Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
|
|
CA3009852A1
(en)
|
2015-12-28 |
2017-07-06 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
TWI756204B
(zh)
|
2016-02-12 |
2022-03-01 |
比利時商楊森製藥公司 |
抗ｖｉｓｔａ抗體及片段、其用途及鑑定其之方法
|
|
WO2017149515A1
(en)
|
2016-03-04 |
2017-09-08 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
|
EP3443096B1
(en)
|
2016-04-15 |
2023-03-01 |
Novartis AG |
Compositions and methods for selective expression of chimeric antigen receptors
|
|
BR112018071153A2
(pt)
|
2016-04-15 |
2019-04-16 |
Immunext, Inc. |
anticorpos anti-vista humano e uso dos mesmos
|
|
WO2017223419A1
(en)
|
2016-06-24 |
2017-12-28 |
Ig Biosciences Corporation |
Prebiotic neutraceutical compositions and methods of treatment using the same
|
|
MA45668A
(fr)
|
2016-07-13 |
2019-05-22 |
Biogen Ma Inc |
Schémas posologiques d'antagonistes de lingo-1 et leurs utilisations pour le traitement de troubles de démyélinisation
|
|
CN110461315B
(zh)
|
2016-07-15 |
2025-05-02 |
诺华股份有限公司 |
使用与激酶抑制剂组合的嵌合抗原受体治疗和预防细胞因子释放综合征
|
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
|
IL316970A
(en)
|
2016-07-28 |
2025-01-01 |
Novartis Ag |
Combination therapies of chimeric antigen receptors and PD-1 inhibitors
|
|
KR20190036551A
(ko)
|
2016-08-01 |
2019-04-04 |
노파르티스 아게 |
Pro-m2 대식세포 분자의 억제제를 병용하는, 키메라 항원 수용체를 이용한 암의 치료
|
|
SG11201901059QA
(en)
|
2016-09-07 |
2019-03-28 |
Glaxosmithkline Ip Dev Ltd |
Methods for purifying antibodies
|
|
US11453726B2
(en)
|
2016-09-15 |
2022-09-27 |
Quadrucept Bio Limited |
Multimers, tetramers and octamers
|
|
WO2018067992A1
(en)
|
2016-10-07 |
2018-04-12 |
Novartis Ag |
Chimeric antigen receptors for the treatment of cancer
|
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
|
CN110167964B
(zh)
|
2016-11-02 |
2023-12-01 |
百时美施贵宝公司 |
组合用于治疗多发性骨髓瘤的针对bcma和cd3的双特异性抗体和免疫药物
|
|
JP7258762B2
(ja)
*
|
2016-11-07 |
2023-04-17 |
デーゲンエルイックス べスローテン フェンノートシャップ |
新規アミロイドベータオリゴマー特異的結合分子
|
|
US11535662B2
(en)
|
2017-01-26 |
2022-12-27 |
Novartis Ag |
CD28 compositions and methods for chimeric antigen receptor therapy
|
|
EP3589647A1
(en)
|
2017-02-28 |
2020-01-08 |
Novartis AG |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
|
US11155612B2
(en)
|
2017-04-21 |
2021-10-26 |
Centro De Investigación Científica Y De Educación Superior De Ensenada, Baja California |
vNAR antibody which binds VEGF for use in dogs or cats
|
|
US20200055948A1
(en)
|
2017-04-28 |
2020-02-20 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
WO2019000223A1
(en)
|
2017-06-27 |
2019-01-03 |
Nanjing Legend Biotech Co., Ltd. |
ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
|
|
WO2019063726A1
(en)
|
2017-09-27 |
2019-04-04 |
Elasmogen Ltd |
SPECIFIC BINDING MOLECULES
|
|
CN111566124A
(zh)
|
2017-10-25 |
2020-08-21 |
诺华股份有限公司 |
制备表达嵌合抗原受体的细胞的方法
|
|
WO2019089798A1
(en)
|
2017-10-31 |
2019-05-09 |
Novartis Ag |
Anti-car compositions and methods
|
|
GB201721802D0
(en)
|
2017-12-22 |
2018-02-07 |
Almac Discovery Ltd |
Ror1-specific antigen binding molecules
|
|
JP7369127B2
(ja)
|
2017-12-28 |
2023-10-25 |
ナンジン レジェンド バイオテック カンパニー，リミテッド |
Ｔｉｇｉｔに対する単一ドメイン抗体及びその変異体
|
|
WO2019139987A1
(en)
|
2018-01-09 |
2019-07-18 |
Elstar Therapeutics, Inc. |
Calreticulin binding constructs and engineered t cells for the treatment of diseases
|
|
KR20250114571A
(ko)
|
2018-01-15 |
2025-07-29 |
난징 레전드 바이오테크 씨오., 엘티디. |
Pd-1에 대한 단일-도메인 항체 및 이의 변이체
|
|
EP3746116A1
(en)
|
2018-01-31 |
2020-12-09 |
Novartis AG |
Combination therapy using a chimeric antigen receptor
|
|
TW202003555A
(zh)
|
2018-03-07 |
2020-01-16 |
英商葛蘭素史克智慧財產發展有限公司 |
用於純化重組多肽之方法
|
|
TW202000891A
(zh)
|
2018-03-07 |
2020-01-01 |
英商葛蘭素史克智慧財產發展有限公司 |
純化抗體之方法
|
|
US12152073B2
(en)
|
2018-03-14 |
2024-11-26 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
US11958903B2
(en)
|
2018-03-30 |
2024-04-16 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies against LAG-3 and uses thereof
|
|
WO2019210153A1
(en)
|
2018-04-27 |
2019-10-31 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
TWI890660B
(zh)
|
2018-06-13 |
2025-07-21 |
瑞士商諾華公司 |
Bcma 嵌合抗原受體及其用途
|
|
US12258414B2
(en)
*
|
2018-06-22 |
2025-03-25 |
Ossianix, Inc. |
Anti-CD98hc VNARs for crossing the blood brain barrier and type IV VNAR libraries
|
|
CN112955465A
(zh)
|
2018-07-03 |
2021-06-11 |
马伦戈治疗公司 |
抗tcr抗体分子及其用途
|
|
SG11202101825QA
(en)
|
2018-08-31 |
2021-03-30 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
WO2020047449A2
(en)
|
2018-08-31 |
2020-03-05 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
WO2020056327A1
(en)
|
2018-09-14 |
2020-03-19 |
Ossianix, Inc. |
Tfr-specific binding moieties and transcytosis method to select vnars that cross cellular barriers
|
|
CN113508127A
(zh)
|
2018-11-06 |
2021-10-15 |
阿尔萨泰克公司 |
神经变性疾病的基于细胞的基因疗法
|
|
CN119039441A
(zh)
|
2019-02-21 |
2024-11-29 |
马伦戈治疗公司 |
与nkp30结合的抗体分子及其用途
|
|
CN119661722A
(zh)
|
2019-02-21 |
2025-03-21 |
马伦戈治疗公司 |
结合t细胞相关癌细胞的多功能分子及其用途
|
|
US20220088075A1
(en)
|
2019-02-22 |
2022-03-24 |
The Trustees Of The University Of Pennsylvania |
Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
|
|
GB201903767D0
(en)
|
2019-03-19 |
2019-05-01 |
Quadrucept Bio Ltd |
Multimers, tetramers & octamers
|
|
US20220168389A1
(en)
|
2019-04-12 |
2022-06-02 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
AR120566A1
(es)
|
2019-11-26 |
2022-02-23 |
Novartis Ag |
Receptores de antígeno quiméricos y sus usos
|
|
GB2609554B
(en)
|
2020-01-03 |
2025-08-20 |
Marengo Therapeutics Inc |
Anti-TCR antibody molecules and uses thereof
|
|
WO2021163618A1
(en)
|
2020-02-14 |
2021-08-19 |
Novartis Ag |
Method of predicting response to chimeric antigen receptor therapy
|
|
AR121461A1
(es)
|
2020-02-27 |
2022-06-08 |
Novartis Ag |
Métodos para la fabricación de células que expresan el receptor de antígeno quimérico
|
|
KR20220147109A
(ko)
|
2020-02-27 |
2022-11-02 |
노파르티스 아게 |
키메라 항원 수용체 발현 세포의 제조 방법
|
|
WO2021190980A1
(en)
|
2020-03-22 |
2021-09-30 |
Quadrucept Bio Limited |
Multimers for viral strain evolution
|
|
CA3187267A1
(en)
|
2020-06-17 |
2021-12-23 |
Janssen Biotech, Inc. |
Materials and methods for the manufacture of pluripotent stem cells
|
|
CN112301431B
(zh)
*
|
2020-08-12 |
2023-01-31 |
华东理工大学 |
基于鲨鱼抗体可变区v-nar的噬菌体文库及其构建方法
|
|
GB202020152D0
(en)
|
2020-12-18 |
2021-02-03 |
Elasmogen Ltd |
Fast-track humanisation of specific binding molecules
|
|
WO2022184659A1
(en)
|
2021-03-01 |
2022-09-09 |
Quadrucept Bio Limited |
Antibody domains & multimers
|
|
US20230174651A1
(en)
|
2021-06-23 |
2023-06-08 |
Janssen Biotech, Inc. |
Materials and methods for hinge regions in functional exogenous receptors
|
|
JP2025525612A
(ja)
|
2022-07-22 |
2025-08-05 |
ヤンセン バイオテツク，インコーポレーテツド |
エフェクター免疫細胞への遺伝的命令の増強された移入
|
|
KR20250067174A
(ko)
|
2022-09-15 |
2025-05-14 |
노파르티스 아게 |
키메라 항원 수용체 요법을 사용한 자가면역 장애의 치료
|
|
GB202216503D0
(en)
|
2022-11-05 |
2022-12-21 |
Quadrucept Bio Ltd |
Non-human vertebrates & cells
|
|
WO2024200846A1
(en)
|
2023-03-30 |
2024-10-03 |
272BIO Limited |
Gnrh-binding polypeptides and uses thereof
|
|
WO2025034806A1
(en)
|
2023-08-08 |
2025-02-13 |
Wisconsin Alumni Research Foundation |
Single-domain antibodies and variants thereof against fibroblast activation protein
|
|
WO2025178959A1
(en)
|
2024-02-20 |
2025-08-28 |
University Of Georgia Research Foundation, Inc. |
Single-domain antibodies and variants thereof against tab1
|